0001104659-13-081324.txt : 20131105
0001104659-13-081324.hdr.sgml : 20131105
20131105204855
ACCESSION NUMBER: 0001104659-13-081324
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131105
FILED AS OF DATE: 20131105
DATE AS OF CHANGE: 20131105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
BUSINESS PHONE: 508-975-4820
MAIL ADDRESS:
STREET 1: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAKIANATHAN DEEPIKA
CENTRAL INDEX KEY: 0001270734
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 131194397
MAIL ADDRESS:
STREET 1: 3000 SAND HILL RD, BLDG 1, STE 135
STREET 2: C/O DELPHI VENTURES
CITY: MENLO PARK
STATE: CA
ZIP: 94025
3
1
a3.xml
3
X0206
3
2013-11-05
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001270734
PAKIANATHAN DEEPIKA
DELPHI VENTURES, 3000 SAND HILL RD,
BLDG 1, STE 135
MENLO PARK
CA
94025
1
0
0
0
Series B Convertible Preferred Stock
Common Stock
1500500
I
By Delphi Ventures VIII, L.P.
Series B Convertible Preferred Stock
Common Stock
14652
I
By Delphi Bioinvestments VIII, L.P.
Series B-1 Convertible Preferred Stock
Common Stock
272818
I
By Delphi Ventures VIII, L.P.
Series B-1 Convertible Preferred Stock
Common Stock
2663
I
By Delphi Bioinvestments VIII, L.P.
The Series B Convertible Preferred Stock is convertible into Common Stock on a 1-for-3.3 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein.
The Series B-1 Convertible Preferred Stock is convertible into Common Stock on a 1-for-3.3 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
/s/ Deepika R.Pakianathan
2013-11-05